Clinical Trial Update: Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating safety and efficacy of CD19 CAR-T cell therapy for refractory membranous nephropathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Nephropathy

Drugs mentioned

• CD19 CAR-T therapy (CD19-targeted CAR-T cell therapy)

Snippet

Sponsor: The First Affiliated Hospital of Air Force Medicial University | Conditions: Refractory Membranous Nephropathy | Phase 1 | Status: RECRUITING